BR112023016442A2 - Composições de soluções aquosas para aumentar a estabilidade de proteínas diméricas modificadas - Google Patents
Composições de soluções aquosas para aumentar a estabilidade de proteínas diméricas modificadasInfo
- Publication number
- BR112023016442A2 BR112023016442A2 BR112023016442A BR112023016442A BR112023016442A2 BR 112023016442 A2 BR112023016442 A2 BR 112023016442A2 BR 112023016442 A BR112023016442 A BR 112023016442A BR 112023016442 A BR112023016442 A BR 112023016442A BR 112023016442 A2 BR112023016442 A2 BR 112023016442A2
- Authority
- BR
- Brazil
- Prior art keywords
- stability
- increase
- proteins
- aqueous solution
- compositions
- Prior art date
Links
- 239000007864 aqueous solution Substances 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 108060003951 Immunoglobulin Proteins 0.000 abstract 2
- 102000018358 immunoglobulin Human genes 0.000 abstract 2
- 102000008847 Serpin Human genes 0.000 abstract 1
- 108050000761 Serpin Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2102258.7A GB202102258D0 (en) | 2021-02-17 | 2021-02-17 | Novel composition |
| PCT/US2022/016864 WO2022178175A1 (en) | 2021-02-17 | 2022-02-17 | Aqueous solution compositions for increasing stability of engineered dimeric proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023016442A2 true BR112023016442A2 (pt) | 2023-10-10 |
Family
ID=75338972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023016442A BR112023016442A2 (pt) | 2021-02-17 | 2022-02-17 | Composições de soluções aquosas para aumentar a estabilidade de proteínas diméricas modificadas |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20220265788A1 (https=) |
| EP (1) | EP4294372A1 (https=) |
| JP (1) | JP2024506718A (https=) |
| KR (1) | KR20230147140A (https=) |
| CN (1) | CN117279624A (https=) |
| AU (1) | AU2022224607A1 (https=) |
| BR (1) | BR112023016442A2 (https=) |
| CA (1) | CA3208704A1 (https=) |
| GB (1) | GB202102258D0 (https=) |
| IL (1) | IL305142A (https=) |
| MX (1) | MX2023009630A (https=) |
| WO (1) | WO2022178175A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023225513A1 (en) * | 2022-05-16 | 2023-11-23 | Inhibrx, Inc. | Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1478394T1 (sl) * | 2002-02-27 | 2008-12-31 | Immunex Corp | STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM |
| KR101235507B1 (ko) * | 2003-02-28 | 2013-02-20 | 추가이 세이야쿠 가부시키가이샤 | 단백질을 함유하는 안정화 제제 |
| ATE530165T1 (de) * | 2003-11-14 | 2011-11-15 | Baxter Int | Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen |
| PL1789434T3 (pl) * | 2004-08-31 | 2014-07-31 | Novo Nordisk As | Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek |
| BRPI0611901A2 (pt) * | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| AU2006318583A1 (en) * | 2005-11-22 | 2007-05-31 | Wyeth | Immunoglobulin fusion protein formulations |
| GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| EP2598167B1 (en) * | 2010-07-30 | 2015-04-01 | Arecor Limited | Stabilized aqueous antibody compositions |
| EA201391489A1 (ru) * | 2011-04-07 | 2014-02-28 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Композиции со сниженной вязкостью |
| KR102231139B1 (ko) | 2011-06-28 | 2021-03-24 | 인히브릭스, 인크. | 세르핀 융합 폴리펩타이드 및 이의 이용 방법 |
| CA2896951A1 (en) * | 2012-01-10 | 2013-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| US9527890B2 (en) * | 2013-06-18 | 2016-12-27 | The Brigham And Womens's Hospital, Inc. | FC receptor (FcRn) binding peptides and uses thereof |
| RU2727639C2 (ru) * | 2014-01-15 | 2020-07-22 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а |
| EP3155117A4 (en) * | 2014-06-11 | 2017-11-22 | Beth Israel Deaconess Medical Center, Inc. | Alpha1-antitrypsin compositions and methods of treating autoimmune diseases |
| NZ769391A (en) * | 2014-10-27 | 2024-12-20 | Sanofi Aatd Inc | Serpin fusion polypeptides and methods of use thereof |
| GB201703063D0 (en) * | 2017-02-24 | 2017-04-12 | Arecor Ltd | Stabilized antibody protein solutions |
| GB201721846D0 (en) * | 2017-12-22 | 2018-02-07 | Arecor Ltd | Novel composition |
-
2021
- 2021-02-17 GB GBGB2102258.7A patent/GB202102258D0/en not_active Ceased
-
2022
- 2022-02-17 AU AU2022224607A patent/AU2022224607A1/en active Pending
- 2022-02-17 KR KR1020237031527A patent/KR20230147140A/ko active Pending
- 2022-02-17 JP JP2023549616A patent/JP2024506718A/ja active Pending
- 2022-02-17 CN CN202280028860.9A patent/CN117279624A/zh active Pending
- 2022-02-17 BR BR112023016442A patent/BR112023016442A2/pt unknown
- 2022-02-17 US US17/674,713 patent/US20220265788A1/en not_active Abandoned
- 2022-02-17 CA CA3208704A patent/CA3208704A1/en active Pending
- 2022-02-17 IL IL305142A patent/IL305142A/en unknown
- 2022-02-17 MX MX2023009630A patent/MX2023009630A/es unknown
- 2022-02-17 EP EP22709101.4A patent/EP4294372A1/en active Pending
- 2022-02-17 WO PCT/US2022/016864 patent/WO2022178175A1/en not_active Ceased
-
2024
- 2024-09-30 US US18/902,711 patent/US20250177501A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220265788A1 (en) | 2022-08-25 |
| IL305142A (en) | 2023-10-01 |
| CN117279624A (zh) | 2023-12-22 |
| CA3208704A1 (en) | 2022-08-25 |
| JP2024506718A (ja) | 2024-02-14 |
| KR20230147140A (ko) | 2023-10-20 |
| EP4294372A1 (en) | 2023-12-27 |
| GB202102258D0 (en) | 2021-03-31 |
| US20250177501A1 (en) | 2025-06-05 |
| AU2022224607A1 (en) | 2023-08-31 |
| MX2023009630A (es) | 2023-11-06 |
| WO2022178175A1 (en) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Anraku et al. | Stabilizing mechanisms in commercial albumin preparations: octanoate and N-acetyl-L-tryptophanate protect human serum albumin against heat and oxidative stress | |
| BRPI0412633A (pt) | composição comestìvel, uso de um agente espessante biopolimérico e método para induzir saciedade | |
| EA201590611A1 (ru) | Новые молекулы, связывающие il-17a, и их медицинское применение | |
| BRPI0416544A (pt) | proteìna de ligação de gag | |
| Mann et al. | The molecular weights of bovine thrombin and its primary autolysis products | |
| WO2022207839A3 (en) | Stabilized pre-fusion piv3 f proteins | |
| BR0012919A (pt) | Vacina para uso na profilaxia e/ou no tratamento da sìndrome de ponto branco (white spot syndrome) em crustáceos, proteìna estrutural derivada do vìrus da sìndrome de ponto branco, sequência de ácido nucléico, uso de uma proteìna estrutural, composição farmacêutica, anticorpos, vacina ou formulação farmacêutica, e, kit diagnóstico para detecção de wssv | |
| BR112023016442A2 (pt) | Composições de soluções aquosas para aumentar a estabilidade de proteínas diméricas modificadas | |
| BR112015017797A2 (pt) | celobio-hidrolase termoestável | |
| BR112022010321A2 (pt) | Composições e métodos para tratamento de neuropatia óptica hereditária de leber com proteínas nadh desidrogenase | |
| BR112023019228A2 (pt) | Peptídeo e composição contendo o peptídeo | |
| Nuhu et al. | Arginine dipeptides affect insulin aggregation in a pH‐and ionic strength‐dependent manner | |
| US12396943B2 (en) | Hemopexin formulations | |
| Frappier et al. | Actin and neurofilament binding domain of brain spectrin β subunit | |
| EA201391546A1 (ru) | Противораковый слитый белок | |
| MX2024008983A (es) | Polipeptidos quimericos | |
| CL2023000004A1 (es) | Formulación en concentración alta de proteínas de unión a antígeno del factor xii | |
| CN105424946A (zh) | 一种含迷迭香酸的凝血酶时间测定试剂 | |
| Raynal et al. | Hydrodynamic characterization of recombinant human fibrinogen species | |
| MX381978B (es) | Composición de inmunoglobulina de alta concentración para aplicación farmacéutica. | |
| Fu et al. | 4, 4′-Dianilino-1, 1′-binaphthyl-5, 5′-sulfonate, a novel molecule having chaperone-like activity | |
| BR112022000847A2 (pt) | Método para inativação viral | |
| BRPI0608020A2 (pt) | processo para a produção de uma composição contendo proteìna de soja e composição contendo proteìna de soja | |
| BR112022021750A2 (pt) | Anticorpo monoclonal anti-apc, material biológico relacionado ao anticorpo monoclonal anti-apc, produto de preparação e uso do anticorpo monoclonal anti-apc ou do material biológico | |
| Brand et al. | Equilibrium dialysis and circular dichroic analysis of the novobiocin-bovine serum albumin complex |